Search results for

The Russian companies Russky Standart Vodka, LVZ Topaz and Sibirsky LVZ produce vodka and are competitors in the market. Topaz and Sibirsky produce and sell vodkas like Green Mark Traditional Recipe, Green Mark Rye and others. The neck of every bottle of those brands carries a collar reading "Vodka No 1 in Russia". It is obviously implied that Topaz and Sibirsky produce the best quality vodkas on the Russian market. The Russian Antimonopoly Service is a watchdog for incorrect marketing practices and directed its attention to that statement.

It is established practice to judge the inventive step of an invention using the problem-solution approach developed within the European patent office. Under this approach, a claimed invention has to add an extra feature to the closest prior art. This additional feature defines the problem to be solved by the person skilled in the art. Starting from the closest prior art and facing the problem to be solved, the skilled person has to find a technical solution for the problem. Whether or not he can do so is part of the inventive step discussion.

Statistics show that the number of cases handled by Norwegian Customs involving goods infringing intellectual property rights, as well as the number of articles seized, is high. Counterfeit products and IP theft have real-world consequences.

According to the current wording of the Mexican IP Law, injunctions can be imposed during the course of an infringement action related to trademarks, patents or slogans, and the plaintiff has to post a bond of an amount fixed by the Patent of Trade Mark Office (IMPI) in order to secure possible damages arising from those injunctions, if the infringement is eventually denied. Likewise, the injunctions can be immediately lifted if the alleged infringer obtains and files a counterbond in favor of the plaintiff.

Under the Korean Patent Act, the inventive step is determined by judging whether the invention could be easily conceived from the prior arts by a person having ordinary skill in the art.

Sherry Knowles spent four years as chief patent counsel at GlaxoSmithKline after more than a decade in private practice. She tells Emma Barraclough what the experience taught her about working for pharmaceutical and biotech companies

R&D-based companies in the life sciences sector face a difficult time. Blockbuster drugs are coming off patent, the pharmaceutical sector continues to face scrutiny from regulators on both sides of the Atlantic, and public scepticism about their right to seek IP protection over innovations related to plants and animals is growing.

Matías Pérez Irazábal of Hoet Pelaez Castillo & Duque discusses the efforts of Customs authorities to prevent the commercialisation of counterfeit products

Aarón Montero and Gabriela Bodden of E-Proint discuss ways to stop ambush marketing and trade mark infringement

Axel Verhauwen and Michael Bergermann of Krieger Mes & Graf v der Groeben explain the advantages that Germany’s specialist courts offer patent litigants